Efficacy dilution in randomized placebo-controlled vaginal microbicide trials

Area of Science:

• Clinical Trials
• HIV Prevention
• Pharmacology

Background:

• Vaginal microbicide gels have not yet proven effective in preventing HIV infection during phase 2b/3 trials.
• Product inefficacy is not the sole reason for trial failures; efficacy dilution can obscure true product effectiveness.

Purpose of the Study:

• To describe and quantify mechanisms of efficacy dilution from various sources in microbicide trials.
• To derive an overall expected effectiveness that accounts for combined dilution effects.

Main Methods:

• Analysis of four individual sources of efficacy dilution.
• Quantification of expected effectiveness under observed trial conditions.
• Calculation of overall expected effectiveness integrating multiple dilution factors.

Main Results:

• With four major dilution sources, expected effectiveness for a 50% efficacious gel drops to 16%-33% and for a 75% efficacious gel to 28%-50%.
• Adherence alone (80%) results in higher expected effectiveness (40% for 50% efficacy, 60% for 75% efficacy).
• Individual dilution sources may seem minor, but their combined effect can substantially reduce observed effectiveness.

Conclusions:

• Planned phase 2b/3 microbicide trials face significant risks from efficacy dilution.
• Interpreting trial results requires a thorough understanding of dilution effects to identify viable products.
• Future trial designs must prioritize reducing and assessing efficacy dilution and carefully select effect sizes.